Exploiting B7-H3: Molecular Insights and Immunotherapeutic Strategies for Osteosarcoma
Yuhang Xie, Hongru Wang, Fanwei Zeng, Yuan Zhang, Jiaye Huang, Chenglong Chen, Shidong Wang · 2025
Read Exploiting B7-H3: Molecular Insights and Immunotherapeutic Strategies for Osteosarcoma by Yuhang Xie, Hongru Wang, Fanwei Zeng, Yuan Zhang, Jiaye Huang, Chenglong Chen, Shidong Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12729273.txt.
Description
Yuhang Xie and six colleagues present a 2025 review on a promising bullseye for bone cancer immunotherapy. Osteosarcoma, the commonest primary bone tumor of teenagers, has seen survival stall for decades. The protein B7-H3 appears abundantly on these tumor cells, tracks with aggression and poor outcomes, and helps tumors hide from the immune system in several ways at once.
Four attack strategies are in play: antibodies, engineered CAR-T cells, antibody-drug conjugates, and bispecific antibodies, each with strengths and gaps. Nanoparticle delivery may patch the gaps by carrying drugs deeper and reshaping the tumor's immune neighborhood. Open problems remain, including the protein's unknown receptor and the tumor's suppressive heterogeneity. The authors map the field's next steps.
Catalog record
| CREATOR | Yuhang Xie, Hongru Wang, Fanwei Zeng, Yuan Zhang, Jiaye Huang, Chenglong Chen, Shidong Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |